Friday 2 October 2015, Amsterdam
The report, now available on ASDReports, The report recognizes the following companies as the key players in the Global HER2-Negative Breast Cancer Market: F. Hoffmann-La Roche, Novartis and Pfizer
Other Prominent Vendors in the market are: AbbVie, AstraZeneca, BioMarin, Bristol-Myers Squibb, Eisai, Eli Lilly, Galena Biopharma, Incyte, Merck, Merck Serono, Merrimack, Nektar, and Tesaro.
Commenting on the report, an analyst said: “An increase in the patient assistance programs by government organizations and vendors will also boost the market growth. These programs are customized to meet the needs of patients who are unable to afford the expensive therapies.
According to the report, the market is expected to grow because of the significant unmet medical needs across the globe. There has been a growth in the demand for various drugs to treat and prevent HER2-negative breast cancer progression. The present therapies also exhibit several safety issues, which decreases patient compliance. This presents an opportunity for drug makers to develop a therapy that can treat the cancer with better efficacy and safety parameters.
Further, the report states that the market growth may be hampered because of the use of premium-priced therapies. The drugs used to treat HER2-negative breast cancer, including biologic therapies, are expensive. This could lead to treatment withdrawal by patients.
The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.
ASDReports.com Media contact: S. Koopman -
Marketing and Communications
ASDReports.com / ASDMedia BV - Veemkade 356 - 1019HD Amsterdam - The Netherlands
P : +31(0)20 486 1286 - F : +31(0)20 486 0216 - E : firstname.lastname@example.org
back to News